Education
About Us
Working with TipRanks
Follow Us
Abbvie (ABBV)
:ABBV
ABBV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$163.81 - $218.66
Previous CloseN/A
Volume1.02M
Average Volume (3M)6.20M
Market Cap
$339.94B
Enterprise Value$340.28B
Total Cash (Recent Filing)$5.18B
Total Debt (Recent Filing)$69.89B
Price to Earnings (P/E)82.1
Beta0.33
Next Earnings
Jul 31, 2025EPS Estimate
2.99Last Dividend Ex-Date
Jul 15, 2025Dividend Yield3.41%
Share Statistics
EPS (TTM)2.46
Shares Outstanding1,766,403,100
10 Day Avg. Volume5,557,673
30 Day Avg. Volume6,204,033
Financial Highlights & Ratios
PEG Ratio9.22
Price to Book (P/B)16.59
Price to Sales (P/S)0.00
P/FCF Ratio11.80
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.52
Enterprise Value/Gross Profit7.66
Enterprise Value/Ebitda4.11
Forecast
1Y Price Target
$212.00Price Target Upside10.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
AbbVie News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's valuation is considered attractive relative to its growth profile, suggesting potential for investment appreciation.
Growth PotentialSkyrizi and Rinvoq continue to trend ahead of expectations, indicating ongoing growth potential for AbbVie.
Strategic AcquisitionsAbbVie announced a definitive agreement to acquire Capstan Therapeutics for up to $2.1 billion in cash, gaining access to Capstan's lead asset for innovative therapies in autoimmune diseases.
Bears Say
Earnings ImpactAnalyst reduces the estimated earnings per share for the second quarter of 2025 due to an IPR&D charge.
Expense DisclosureAbbVie disclosed a significant IPR&D and milestones expense for the second quarter of 2025.
Pricing ChallengesHumira downside on misunderstood pricing in US, reflecting biosimilar competition erosion and class erosion.
Ownership Overview
0.07% Insiders
20.71% Mutual Funds
14.10% Other Institutional Investors
57.11% Public Companies and Individual Investors
ABBV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was $163.81 and its highest was $218.66 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $339.94B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jul 31, 2025 which is in 15 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Apr 25, 2025. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.379 by $0.081.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $8.015 which represents an annual dividend yield of 3.41%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 2.99.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,403,100 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $2.46 in its last earnings report, beating expectations of $2.379. Following the earnings report the stock price went up 3.155%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in ABBV
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$212.00 (10.69% Upside)
$212.00 (10.69% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 753.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.56%
12-Months-Change
Fundamentals
Return on Equity
88.15%
Trailing 12-Months
Asset Growth
-8.54%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Earnings Call
Q1 2025
0:00 / 0:00
ABBV Stock 12 Month Forecast
Average Price Target
$212.00
▲(10.69%Upside)